NVS tops Q4 EPS estimates as margins expand, but revenues miss the mark amid U.S. generics hitting Entresto and Promacta, ...
Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmaker’s fourth-quarter ...
Novartis (NVS) offers a compelling value opportunity with EPS growth, margin expansion, and a robust pipeline at a discounted ...
Novartis’ fourth-quarter performance saw net sales decline 1% at constant currencies to $13.3 billion, a reflection of the accelerating impact of U.S. competition and revenue deduction adjustments, ...
MSN Laboratories Pvt. Ltd. can’t reopen disputes resolved in earlier litigation over the scope, validity, and infringement of ...
(Reuters) -Novartis failed to convince a federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to ...
After more than six years of high-stakes litigation in multiple courts and regulatory fights at the Food and Drug Administration (FDA), generic versions of Novartis Pharmaceuticals Corp.
Novartis forecast its first annual drop in operating profit in a decade on Wednesday, even as it indicated that long term, the company could potentially offset the patent expiry of its ...
Medicare Part D usually covers Entresto. However, the exact cost of Entresto can vary. In 2022, according to the most recent data, the annual out-of-pocket cost for Entresto for people with Medicare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results